Low dose of ROSuvastatin in combination with EZEtimibe effectively and permanently reduce low density lipoprotein cholesterol concentration independently of timing of administration (ROSEZE): A randomized, crossover study - preliminary results.

Cardiol J · 2021 · PMC8105047 · PMID 33200812

Europe PMC DOI

hedged sentences

0.0001

closest p · 0.0× alpha

0.0001

boldest claim

The sentences

highly significantp < 0.0001actually significant

More powerful statins compared with weaker ones, produce a highly significant 15% (95% confidence interval [CI] 11–18; p < 0.0001) further reduction in major vascular events [ 11 ].

also in 132,142 other papers

did not reach statistical significanceno p-value reported

The reduction in Lp(a) concentration in the current study did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.